🌍 ObsEva SA (company was delisted NASDAQ) (OBSV) - Form 6-K Filing
Filing Date: 2022-07-27
Accepted: 2022-07-27 07:03:30
Event Type: Regulatory Update
Event Details:
ObsEva SA (NASDAQ OBSV SIX OBSN) plans to initiate a corporate restructuring and refocus the Companys development and commercialization strategy. The U.S. Food and Drug Administration (FDA) has notified the Company of review issues regarding deficiencies in the New Drug Application (NDA) for linzagolix for uterine fibroids.
💼 Business Developments:
✅ Partnership/Collaboration
❌ Acquisition Activity: Not reported
✅ Licensing Agreement
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Investor Contact: Katja Buhrer katja.buhrer@obseva.com +1 (917) 969-3438 Media Contact Jeanene Ti
Media Contact: Jeanene Timberlake RooneyPartners jtimberlake@rooneypartners.com +1 (646) 770-8
🌍 ObsEva SA (company was delisted NASDAQ) (OBSV) - Form 6-K Filing
Filing Date: 2022-07-27
Accepted: 2022-07-27 07:03:30
Event Type: Regulatory Update
Event Details:
💼 Business Developments:
📞 Contact Information: